RAS Dialogue
Join the discussion! Post comments, ask questions, and share information with RAS experts. Subscribe to receive notifications when a new RAS Dialogue article is posted.
-
Covalent Inhibitors of RASA “tethered screening” approach is opening new doors to drugging RAS proteins. The NCI RAS Initiative is developing small molecules that covalently modify cysteine-185 and histidine-95 of KRAS.
-
Modeling Treatments for Ras and Raf CancersDetails of how Raf inhibitors interact with their protein targets enable modeling of how drug resistance develops. Together with other biochemical data, computational models predict how to combine inhibitors for more effective cancer treatments.
-
The Stroma of Pancreatic Cancer Supports Proliferation of Tumor CellsPancreatic cancer cells activate stellate cells in their microenvironment, causing them to secrete lipid molecules. Some of these molecules are converted to a potent signaling lipid, which increases cancer growth.
-
Inhibition of MAPK Signaling Increases Autophagy in Mutant RAS CancersCancers driven by mutant RAS genes show increased autophagy. Dual inhibition of RAS signaling and autophagy inhibits RAS cancers.
-
Initiative Spotlight: A Conversation with Frank McCormickRecent discoveries and new approaches are chipping away at the cancers caused by mutant RAS genes. For the first time drugs that target RAS directly are in human clinical trials.